Media headlines about Ardelyx (NASDAQ:ARDX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ardelyx earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.5212185081663 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Ardelyx (NASDAQ ARDX) traded down $0.08 during trading hours on Wednesday, hitting $5.52. 75,818 shares of the stock traded hands, compared to its average volume of 287,516. Ardelyx has a one year low of $4.05 and a one year high of $15.40. The company has a market capitalization of $266.20, a P/E ratio of -2.49 and a beta of 0.76.
A number of research firms recently commented on ARDX. BidaskClub cut shares of Ardelyx from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Cantor Fitzgerald set a $12.00 price objective on shares of Ardelyx and gave the stock a “buy” rating in a research note on Monday, February 12th. Zacks Investment Research downgraded shares of Ardelyx from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. ValuEngine cut shares of Ardelyx from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Citigroup lifted their price objective on shares of Ardelyx from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, November 29th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Ardelyx presently has a consensus rating of “Hold” and a consensus target price of $12.93.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/14/ardelyx-ardx-earning-somewhat-favorable-media-coverage-study-finds/1923773.html.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.